Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological characteristics of patients with microphthalmia t...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Korean Urological Oncology Society 2024-03-01
Σειρά:	Journal of Urologic Oncology
Θέματα:	-rearranged -altered renal cell carcinoma tyrosine kinase inhibitors immune checkpoint inhibitors
Διαθέσιμο Online:	http://www.e-juo.org/upload/pdf/juo-234600660033.pdf

Παρόμοια τεκμήρια

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
ανά: Huang JT, κ.ά.
Έκδοση: (2022-11-01)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
ανά: Pan X, κ.ά.
Έκδοση: (2023-06-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
ανά: Fei Yang, κ.ά.
Έκδοση: (2022-01-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
ανά: Hongyu Pan, κ.ά.
Έκδοση: (2025-03-01)

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors
ανά: A. Yu. Goryainova, κ.ά.
Έκδοση: (2021-12-01)

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
ανά: Gao B, κ.ά.
Έκδοση: (2023-12-01)

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
ανά: Ning Luo, κ.ά.
Έκδοση: (2023-08-01)

Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma: Protocol for a rapid systematic review
ανά: Shannon E. Kelly, κ.ά.
Έκδοση: (2024-06-01)

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
ανά: Guosheng Yuan, κ.ά.
Έκδοση: (2024-03-01)

Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
ανά: Sang Youn Hwang, κ.ά.
Έκδοση: (2023-11-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
ανά: Christopher Kwok, κ.ά.
Έκδοση: (2023-07-01)

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
ανά: Junfeng Bu, κ.ά.
Έκδοση: (2025-02-01)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
ανά: Karam Khaddour, κ.ά.
Έκδοση: (2020-10-01)

Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
ανά: Yiwan Guo, κ.ά.
Έκδοση: (2024-01-01)

Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
ανά: David O’Reilly, κ.ά.
Έκδοση: (2024-07-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
ανά: Yifan Zhang, κ.ά.
Έκδοση: (2024-06-01)

Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors
ανά: Shasha Sun, κ.ά.
Έκδοση: (2024-12-01)

Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
ανά: Emmy D. G. Fleuren, κ.ά.
Έκδοση: (2021-11-01)

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report
ανά: Jian Wang, κ.ά.
Έκδοση: (2024-12-01)

Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
ανά: Changjie Du, κ.ά.
Έκδοση: (2024-05-01)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
ανά: Renguo Guan, κ.ά.
Έκδοση: (2022-09-01)

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
ανά: Yuhang Chen, κ.ά.
Έκδοση: (2024-12-01)

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
ανά: Qiao Ke, κ.ά.
Έκδοση: (2022-05-01)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
ανά: Ling Peng, κ.ά.
Έκδοση: (2022-04-01)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
ανά: Yue Chen, κ.ά.
Έκδοση: (2022-06-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
ανά: Halil Ibrahim Onder, κ.ά.
Έκδοση: (2014-04-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
ανά: Ichiro Yamauchi, κ.ά.
Έκδοση: (2025-01-01)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
ανά: Daniela R. Montagna, κ.ά.
Έκδοση: (2022-08-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
ανά: Pottayil G. Sasikumar, κ.ά.
Έκδοση: (2020-12-01)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
ανά: Ryo Ariyasu, MD, κ.ά.
Έκδοση: (2023-06-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
ανά: Yi-fan Chen, κ.ά.
Έκδοση: (2011-12-01)

A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
ανά: Kexue Deng, κ.ά.
Έκδοση: (2022-09-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
ανά: Jingyang Su, κ.ά.
Έκδοση: (2024-04-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
ανά: Eva Zhang, κ.ά.
Έκδοση: (2021-05-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
ανά: CHEN Shuangqing, κ.ά.
Έκδοση: (2022-10-01)

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature
ανά: Qi Zhu, κ.ά.
Έκδοση: (2022-05-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
ανά: Hanping Wang, κ.ά.
Έκδοση: (2020-01-01)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
ανά: Yuanquan Yang, κ.ά.
Έκδοση: (2022-08-01)

Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors
ανά: João Queirós Coelho, κ.ά.
Έκδοση: (2024-10-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
ανά: Hor-Yue Tan, κ.ά.
Έκδοση: (2018-02-01)